Low Levels = Better Brain Function
In their laboratory culture and mice studies they found these three microRNAs influenced inflammatory processes in the brain, and its plasticity – the ability of neurons to adapt, reorganize and make new connections. Changes in these microRNAs can therefore reflect multiple yet interdependent key processes linked to cognitive function and decline. In cognitive tests given to healthy adults, those with low blood levels of these molecules performed better. In mice, these levels increased even before mental decline set in, whether this was due to advanced age or because they developed Alzheimer’s-like symptoms is not yet known. Additional evidence for the value of this blood marker came from patients with mild cognitive impairment. In those with highly elevated levels, nearly nine out of ten developed Alzheimer’s disease within two years. Professor André Fischer, who led the research, said that increased levels are “a harbinger of dementia,” and estimates that “in humans this biomarker indicates a development that is about two to five years in the future.” He also believes microRNA’s influence on inflammation and plasticity suggests these molecules do much more than act as warning signals. It’s why professor Fischer believes they might be important in the successful treatment of dementia.Potential to Reverse Alzheimer’s
“In our view,” professor Fischer stated, “they are not only markers but also have an active impact on pathological processes. This makes them potential targets for therapy. “Indeed, we see in mice that learning ability improves when these microRNAs are blocked with drugs. We’ve observed this in mice with age-related mental deficits as well as in mice with brain damage similar to that occurring in Alzheimer’s disease.” In their paper published in the journal EMBO Molecular Medicine in October, the researchers wrote that their data provides “unprecedented evidence” for the validity of this biomarker to “inform about the cognitive status and reserve and help to detect individuals at risk for pathological memory impairment.” The marker requires further testing, but assuming these are successful, professor Fischer explains, “we intend to develop a simple test procedure for point-of-care screening. Our goal is to have a low-cost test similar to the rapid test for SARS-Cov-2 [COVID-19] with the difference that for our purposes you would need a drop of blood. “Such a test could be used during routine checkups in doctors’ practices to detect an elevated risk of dementia early on. Individuals with suspicious results could then undergo more elaborate diagnostics.”